PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.

  title={PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.},
  author={Andrea Cercek and Melissa A Lumish and Jenna Sinopoli and Jill Weiss and Jinru Shia and Michelle F Lamendola-Essel and Imane El Dika and Neil H. Segal and Marina Shcherba and Ryan Sugarman and Zsofia K. Stadler and Rona Yaeger and J. Joshua Smith and Beno{\^i}t Rousseau and Guillem Argil{\'e}s and Miteshkumar Patel and Avni Mukund Desai and Leonard B. Saltz and Maria Widmar and Krishna Iyer and Janie Y Zhang and Nicole Gianino and Christopher Crane and Paul B. Romesser and Emmanouil P. Pappou and Philip P. Paty and Julio Garcia-Aguilar and Mithat Gonen and Marc J. Gollub and Martin R. Weiser and Kurt A. Schalper and Luis A. Diaz},
  journal={The New England journal of medicine},
BACKGROUND Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair-deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair-deficient, locally advanced… 

Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer

Preliminary evidence for the revolutionary therapeutic transition from neoadjuvant chemotherapy/radiotherapy followed by surgery to immunotherapy followedby nonoperative management in patients with mismatch repair – de fi cient (dMMR), locally advanced rectal cancer is presented.

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.

Neoadjuvant therapy with PD-1 blockade is highly effective for localized dMMR CRC, with an acceptable safety profile and low recurrence rate, and this treatment holds promise for becoming the new standard of care for localization d MMR CRCs.

The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients

The rationale, results, and limitations of the most remarkable trials assessing ICIs in dMMR/MSI-H and pMMR-L localized rectal cancer patients are presented, at the same time highlighting the most promising research perspectives that have followed these studies.

Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report

A case of dMMR and MSI-H LARC with KRAS mutation that achieved pathological complete response of primary lesion and liver metastases after neoadjuvant short-course radiotherapy followed by four cycles chemotherapy of XELOX plus PD-1 inhibitor tislelizumab and a subsequent total mesorectal excision indicates that this combined treatment strategy has remarkable clinical response both in locoregional and distant diseases.

How We Treat Localized Rectal Cancer—An Institutional Paradigm for Total Neoadjuvant Therapy

An institutional treatment algorithm is developed which may serve as a practical tool for treating physicians without any claim to general validity and be sufficient to adopt the concept of TNT and immunotherapy in clinical practice.

Tumor Microenvironment before and after Chemoradiation in Locally Advanced Rectal Cancer: Beyond PD-L1

Assessing the change in biomarkers associated with TME following standard neoadjuvant cCRT in rectal cancer suggests that the biomarkers noted to be upregulated could be used for designing appropriate clinical trials and development of therapeutic targeted drug therapy in an effort to achieve better response to neoadedjuvant therapy, increasing clinical and pathological complete response rates and improved overall outcomes.

Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location.

This review attempts to frame the rapidly growing data in LARC in context of disease and patient risk factors, to inform optimal, personalized treatment of patients with LARC.

Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review

A case of anticancer drug-resistant MSI-high colon cancer that was resected after treatment with immune checkpoint inhibitors, and a pCR was achieved is reported, indicating a new treatment strategy can be used for the treatment of cases that are not responsive to conventional therapies.



Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer.

FOLFOX and chemoradiation before planned TME results in tumor regression, a high rate of delivery of planned therapy, and a substantial rate of pathCRs, and offers a good platform for nonoperative management in select patients.

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

The data indicate that neoadjuvant immunotherapy may have the potential to become the standard of care for a defined group of colon cancer patients when validated in larger studies with at least 3 years of disease-free survival data.

Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy

A WW strategy for select rectal cancer patients who had a clinical complete response after neoadjuvant therapy resulted in excellent rectal preservation and pelvic tumor control; however, in the WW group, worse survival was noted along with a higher incidence of distant progression in patients with local reg growth vs those without local regrowth.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Evaluating the efficacy of PD-1 blockade in patients with advanced mismatch repair–deficient cancers across 12 different tumor types showed that colorectal cancers with mismatch repair deficiency were sensitive to immune checkpoint blockade with antibodies to programmed death receptor–1 (PD-1).

Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy: Long-term Results

Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy and Surgical resection may not lead to improved outcome in this situation and may be associated with high rates of temporary or definitive stoma construction and unnecessary morbidity and mortality rates.

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

Oncodistinct 004 – AURA is an ongoing multicenter phase II randomized trial assessing the efficacy and safety of avelumab single-agent or combined to different NAC regimens in patients with non-metastatic MIBC.

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma

The feasibility of neoadjuvant immune checkpoint blockade in melanoma is described and the need for additional studies to optimize treatment regimens and to validate putative biomarkers is emphasized.

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

In patients with pCR, near pCR or partial pathological response with immunotherapy, very few relapses were seen, and, at this writing, no patient has died from melanoma.

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

It is found that the co-occurrence of tumour-associated CD8 + T cells and CD20 + B cells, and the formation of tertiary lymphoid structures, are linked with improved survival in cohorts of patients with metastatic melanoma.